INDIANAPOLIS, May 1 /PRNewswire/ -- In the news release, "Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008", issued earlier today by Eli Lilly and Company (NYSE: LLY) over PR Newswire, the company logo referenced at the bottom of the press release was incorrectly transmitted by PR Newswire. Please access the correct company logo at http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO . PR Newswire regrets any confusion or inconvenience resulting from this error. Complete, corrected release follows:
-- ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included in May 15 ASCO Live, Online Presscast
Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research.
Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.
"Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care."
Key Pemetrexed Abstracts for ASCO 2008:
-- Abstract # 8011: June 2, 2008; 3:00 p.m.
-- Maintenance pemetrexed plus best supportive care (BSC) versus
placebo plus BSC: A phase III study
-- This study will be featured during ASCO presscast on May 15
-- Abstract # 8096: June 1, 2008; 2:00 p.m.
-- Comparison of patient outcomes stratified by histology among
pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase
II trials
-- Abstract # 8097: June 1, 2008; 2:00 p.m.
-- Resource utilization by non-small cell lung cancer histology:
Results from the randomized, phase III trial of
pemetrexed/cisplatin versus gemcitabine/cisplatin
For more information on Lilly Oncology agents, including full prescribing information, please visit www.lillyoncology.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
Amy Sousa of Eli Lilly and Company, +1-317-276-8478, Mobile: +1-317-997-1481, or Neil Hochman of CPR Worldwide, +1-212-453-2067, Mobile: +1-516-784-9089. Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, PRN Photo Desk, photodesk@prnewswire.com
